Inside Life Sciences

Inside Life Sciences

Issue 6
4579Editor's Note

Editor's Note

Welcome to the Autumn edition of Inside Life Sciences.

Read more
1785New UK regime for medical cannabis

New UK regime for medical cannabis

On 1 November, the new regime for medical cannabis became law in the UK.

Read more
4099Supreme Court upholds insufficiency of pregabalin second medical use patent

Supreme Court upholds insufficiency of pregabalin second medical use patent

In a much anticipated judgment, the Supreme Court has issued its decision in Warner-Lambert v Mylan & Actavis, focussing on how concepts of patent sufficiency and plausibility, and infringement, should be assessed in relation to second medical use patents.

Read more
4100Data theft in the life sciences industry: the importance of taking decisive, and early, action

Data theft in the life sciences industry: the importance of taking decisive, and early, action

As any entity operating in the pharmaceutical sector will be aware, information derived in the course of a research and development project is highly confidential and critical to its success and profitability.

Read more
1780SPCs and combination products: Gilead's Truvada SPC held invalid

SPCs and combination products: Gilead's Truvada SPC held invalid

The UK Patents Court in Teva & ors v Gilead has decided the SPC for Truvada - a fixed-dose combination of two antiretroviral medications (tenofovir disoproxil and emtricitabine) used to treat and prevent HIV infection - is invalid.

Read more
4101The use of artificial intelligence in drug development

The use of artificial intelligence in drug development

Over the years, disease diagnosis, drug development and drug testing have become increasingly inefficient and expensive.

Read more
1748Brexit: Preparations for 'no deal' intensifying

Brexit: Preparations for 'no deal' intensifying

The recent news that a clinical trial for a heart drug was halted due to Brexit concerns have put in sharp focus the significant uncertainty for the industry as a result of a potential no deal.

Read more

Previous Issues

Prev
 
Next

Services

People

How can we help you?

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

Crisis Hotline

Emergency number:

Tel: +44 80 0260 0546

I'm a client

Please enter your first name
Please enter your last name
Please enter your enquiry
Please enter a value

I'm looking for advice

Please enter your first name
Please enter your last name
Please enter your enquiry
Please select a department
Please select a contact method

Something else

Please enter your first name
Please enter your last name
Please enter your enquiry
Please select your contact method of choice